How does pathologic response following neoadjuvant chemotherapy affect survival/recurrence in PCAD

Anirban Maitra shared on X:

“Pathologic complete response following neoadjuvant chemotherapy in Pancreatic Cancer: Impact on survival and recurrence

Authors: Domenico Tamburrino, Claudia Arcangeli, Federico De Stefano, Giulio Belfiori, Marina Macchini, Giulia Orsi, Marco Schiavo Lena, Stefano Partelli, Stefano Crippa, Claudio Doglioni, Michele Reni, Massimo Falconi

This study from Vita-Salute San Raffaele University reiterates what other groups have shown, including this MD Anderson Cancer Center paper:

Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma

Authors: Jordan M. Cloyd, Huamin Wang, Michael E. Egger, Ching-Wei D. Tzeng,  Laura R. Prakash,  Anirban Maitra, Gauri R. Varadhachary, Rachna Shroff, Milind Javle, David Fogelman, Robert A. Wolff, Michael J. Overman, Eugene J. Koay, Prajnan Das, Joseph M. Herman, Michael P. Kim, Jean-Nicolas Vauthey, Thomas A. Aloia, Jason B. Fleming, Jeffrey E. Lee, Matthew H. G. Katz

And The Ohio State University Wexner Medical Center study:

Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes

Authors: Jordan M. Cloyd, Aslam Ejaz, Chengli Shen, Mary Dillhoff, Terence M. Williams, Anne Noonan, Timothy M. Pawlik

Complete pathological response after neoadjuvant therapy in pancreatic cancer is uncommon (<5%) but remains an independent prognostic factor favoring long term survival.”

Source: Anirban Maitra/X

For more posts by Anirban Maitra visit oncodaily.com

Dr. Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.